{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:58:10Z","timestamp":1785581890114,"version":"3.56.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity, but their long-term cancer risks remain controversial in observational studies. We conducted a drug-target Mendelian randomization (MR) analysis using genetic variants in the GLP1R gene region as instruments to proxy GLP-1RA exposure. Summary-level data for 21 cancer types were obtained from public GWAS consortia. Inverse-variance weighted (IVW) MR was used as the primary method, supplemented by sensitivity analyses, Cox proportional hazards regression analyses, and mediation testing for BMI and HbA1c. Genetically proxied GLP-1RA use was associated with a reduced risk of breast cancer [the log of the odds ratio (log{OR})\u00a0=\u00a0\u22120.343,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a06.46\u00a0\u00d7\u00a010\n                      <jats:sup>\u22124<\/jats:sup>\n                      ] and prostate cancer [log(OR)\u00a0=\u00a0\u22120.004,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a02.25\u00a0\u00d7\u00a010\n                      <jats:sup>\u22124<\/jats:sup>\n                      ], but an increased risk of head and neck cancer [log(OR)\u00a0=\u00a00.350,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a01.17\u00a0\u00d7\u00a010\n                      <jats:sup>\u22124<\/jats:sup>\n                      ] and thyroid cancer [log(OR)\u00a0=\u00a01.016,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a09.12\u00a0\u00d7\u00a010\n                      <jats:sup>\u22124<\/jats:sup>\n                      ]. The directions of these effects were validated by the Cox proportional hazards regression model using UK Biobank data and weighted polygenic scores for GLP1R expression, though the association did not reach significance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt;\u00a00.05). Mediation analyses indicated that BMI explained about 3% of the causal effects on endometrial cancer, and HbA1c level explained 3% on head and neck cancer and 4% on thyroid cancer. This MR study provides evidence that GLP-1RA use may causally influence the risk of several cancers. These findings support the need for cancer-specific monitoring in patients using GLP-1RAs and further mechanistic research.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005253","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:00:48Z","timestamp":1781521248000},"page":"4170-4175","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The association between genetically proxied GLP-1 receptor agonists and cancer risks"],"prefix":"10.1097","volume":"88","author":[{"given":"Fei","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yang","sequence":"additional","affiliation":[{"name":"Shanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoying","family":"Xing","sequence":"additional","affiliation":[{"name":"Shanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China"},{"name":"National Center for Liver Cancer, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Zong","sequence":"additional","affiliation":[{"name":"Institute of Nutrition, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Feng","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Jinshan Hospital, Fudan University, Shanghai, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7429-4706","authenticated-orcid":false,"given":"Xin","family":"Geng","sequence":"additional","affiliation":[{"name":"Shanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China"},{"name":"National Center for Liver Cancer, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"R1-20260801","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark Res"},{"key":"R2-20260801","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R3-20260801","doi-asserted-by":"crossref","first-page":"767\u201382","DOI":"10.1016\/j.ajhg.2022.04.001","article-title":"Combining evidence from mendelian randomization and colocalization: review and comparison of approaches","volume":"109","author":"Zuber","year":"2022","journal-title":"Am J Hum Genet"},{"key":"R4-20260801","doi-asserted-by":"crossref","first-page":"1645\u201353","DOI":"10.1002\/jbmr.4880","article-title":"Evaluation of the effect of sodium-glucose cotransporter 2 inhibition on fracture risk: evidence from mendelian randomization and genetic association study","volume":"38","author":"Dai","year":"2023","journal-title":"J Bone Miner Res"},{"key":"R5-20260801","doi-asserted-by":"crossref","first-page":"4688\u201394","DOI":"10.1097\/JS9.0000000000001514","article-title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target mendelian randomization and clinical trials","volume":"110","author":"Sun","year":"2024","journal-title":"Int J Surg"},{"key":"R6-20260801","first-page":"5734\u201336","article-title":"Commentary: association of glucagon-like peptide-1 receptor agonists with risk of cancers evidence from a drug target mendelian randomization and clinical trials","volume":"111","author":"Yang","year":"2025","journal-title":"Int J Surg"},{"key":"R7-20260801","first-page":"100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of artificial intelligence","volume":"10","author":"Agha","journal-title":"Prem J Sci"},{"key":"R8-20260801","doi-asserted-by":"crossref","first-page":"1300\u201310","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis-and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression","volume":"53","author":"V\u00f5sa","year":"2021","journal-title":"Nat Genet"},{"key":"R9-20260801","doi-asserted-by":"crossref","first-page":"203\u201309","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"key":"R10-20260801","doi-asserted-by":"crossref","first-page":"187\u2013225","DOI":"10.1161\/CIRCULATIONAHA.115.018585","article-title":"Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"R11-20260801","doi-asserted-by":"crossref","first-page":"2020\u201328","DOI":"10.1001\/jama.2018.14854","article-title":"The physical activity guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"R12-20260801","doi-asserted-by":"crossref","first-page":"384\u201390","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"R13-20260801","first-page":"891\u2013900","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes and Metab"},{"key":"R14-20260801","doi-asserted-by":"crossref","first-page":"1538\u201347","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: c-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"R15-20260801","doi-asserted-by":"crossref","first-page":"e70490","DOI":"10.1002\/hsr2.70490","article-title":"Association between GLP1 RAs use and risk of colorectal cancer: a systematic review and meta-analysis","volume":"8","author":"Bushi","year":"2025","journal-title":"Health Sci Rep"},{"key":"R16-20260801","doi-asserted-by":"crossref","first-page":"101695","DOI":"10.1016\/j.diabet.2025.101695","article-title":"Reduced risks of colorectal cancer with GLP-1RAs in type 2 diabetes: a nationwide cohort study using a target trial emulation framework","volume":"51","author":"Wu","year":"2025","journal-title":"Diabetes Metab"},{"key":"R17-20260801","doi-asserted-by":"crossref","first-page":"1387243","DOI":"10.3389\/fphar.2024.1387243","article-title":"Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R18-20260801","first-page":"i5340","article-title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK clinical practice research datalink","volume":"355","author":"Hicks","year":"2016","journal-title":"BMJ"},{"key":"R19-20260801","doi-asserted-by":"crossref","first-page":"912\u201321","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","volume":"106","author":"Piccoli","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:04:54Z","timestamp":1785578694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005253","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2026-01-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}